The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Open accessAbstract
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust immune responses. Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver. Here, we screened a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model when administered IM. A subset of compounds was selected and further evaluated for tolerability, immunogenicity, and expression in rodents and non-human primates (NHPs). A lead formulation was identified that yielded a robust immune response with improved tolerability. More importantly for vaccines, increased innate immune stimulation driven by LNPs does not equate to increased immunogenicity, illustrating that mRNA vaccine tolerability can be improved without affecting potency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection31 or in muscle cells after intramuscular (i.m.) injection.32”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [32]
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [291]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“For Moderna's LNP formulation, Hassett et al. reported that the SM-102 lipid was selected based on its improved tolerability profile in non-human primates, as evidenced by a reduced local reactogenicity (e.g., edema and erythema) and lowest induction of systemic cytokine responses (e.g., IL-6) [13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Lanciotti, R. S., Kosoy, O. L., Laven, J. J., Velez, J. O., Lambert, A. J., Johnson, A. J., Stanfield, S. M., & Duffy, M. R. (2008) · Emerging infectious diseases · doi:10.3201/eid1408.080287 · Cited by 2,173
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“8.(11,13,23) However, the best lipids with respect to protein expression after IV administration generally had lower pKas than the best lipids for protein expression after IM administration.”
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. F. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 965
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 918
Advances in non-viral mRNA delivery to the spleen
Narasipura, E. A., & Fenton, O. S. (2024) · Biomaterials Science · doi:10.1039/d4bm00038b · Cited by 20
Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines
Shiraishi, K. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2538423 · Cited by 19
Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy
Kim, H. J., Seo, S. K., & Park, H. Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.029 · Cited by 18
Bakowski, K., & Vogel, S. (2022) · RNA Biology · doi:10.1080/15476286.2022.2147278 · Cited by 18
Luo, J., Zhang, Z., Song, Z., & Gao, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076369 · Cited by 22
Pooter, D. D., Pierson, W., Pourshahian, S., Dockx, K., Clerck, B. D., Nájera, I., Davis, H. L., Gulck, E. R. V., & Boden, D. (2024) · Vaccines · doi:10.3390/vaccines12030237 · Cited by 18
Wolf, M. A., O’Hara, J. M., Bitzer, G. J., Narayanan, E., Boehm, D. T., Bevere, J. R., DeJong, M. A., Hall, J. M., Wong, T. Y., Falcone, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00890-4 · Cited by 18
Self-citationFernandes, R. S., Burle-Caldas, G. D. A., Sérgio, S. A. R., Bráz, A. F., Leite, N. P. D. S., Pereira, M. C. A., Silva, J. D. O., Hojo-Souza, N. S., de Oliveira, B., Fernandes, A. P., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03201-8 · Cited by 20
Nanotechnology-Enabled COVID-19 mRNA Vaccines
Gao, Y., Yang, K., Shelling, A. N., & Wu, Z. (2021) · Encyclopedia · doi:10.3390/encyclopedia1030059 · Cited by 18
Abe, S., Takata, H., Shimizu, T., Kawaguchi, Y., Fukuda, S., Yamamoto, H., Ando, H., & Ishida, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113821 · Cited by 18
Muto, H., Kubara, K., Hitaoka, S., Osada, Y., & Suzuki, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114055 · Cited by 18
CRISPR delivery systems for organ-specific targeting: Advances and challenges
Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 20
Cho, H., Chuang, T.-H., & Wu, S. (2021) · Biomedicines · doi:10.3390/biomedicines9101367 · Cited by 17
Nucleic Acid Vaccines against SARS-CoV-2
Liu, Y., & Ye, Q. (2022) · Vaccines · doi:10.3390/vaccines10111849 · Cited by 17
Licensed liposomal vaccines and adjuvants in the antigen delivery system
Krasnopolsky, Y., & Pylypenko, D. (2022) · Biotechnologia · doi:10.5114/bta.2022.120709 · Cited by 21
Best practices for characterizing RNA lipid nanoparticles
Khan, O. F. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00258-3 · Cited by 17
Kapoor, D. U., Chilkapalli, S. C., Prajapati, B. G., Rodriques, P., Patel, R. J., Singh, S. K., & Bhattacharya, S. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010268824231122041237 · Cited by 17
Ionizable Drugs Enable Intracellular Delivery of Co‐Formulated siRNA
Slaughter, K. V., Donders, E. N., Jones, M. S., Sabbah, S. G., Elliott, M. J., Shoichet, B. K., Cescon, D. W., & Shoichet, M. S. (2024) · Advanced Materials · doi:10.1002/adma.202403701 · Cited by 17
Scialò, F., Vitale, M., Daniele, A., Nigro, E., Perrotta, F., Gelzo, M., Iadevaia, C., Cerqua, F. S., Costigliola, A., Allocca, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9060611 · Cited by 17
Edwards, D. K., & Carfı́, A. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102214 · Cited by 18
Lee, D. W., Nasir, A., Elbashir, S. M., Jani, H., Speidel, T., Gorrie, A., Berrueta, D. M., Martin, P., Tan, S., Hou, Y. J., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126961 · Cited by 16
Vaccine formulation design: challenges and opportunities
Zafar, S., Akhtar, A., Sayed, E., Onaiwu, E., Arshad, M. S., & Ahmad, Z. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00017c · Cited by 17
Direct structural investigation of pH responsiveness in mRNA lipid nanoparticles: Refining paradigms
Wilhelmy, C., Uebbing, L., Kolb, B., Graewert, M. A., Nawroth, T., Haas, H., & Langguth, P. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113848 · Cited by 16
Research progress of mRNA vaccines for infectious diseases
Zhang, Z., Du, J., Zhang, D., Han, R., Wu, X., & Liang, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03060-x · Cited by 19
Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines
Rudra, A., Gupta, A., Reed, K., Deik, A., Min, J., Mansour, H. M. A., Nguyen, Q. T. C., Danko, A., Hu, Y., Berger, A., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02044-6 · Cited by 18
Rood, J. E., Yoon, S. K., Heard, M. K., Carro, S. D., Hedgepeth, E. J., O'Mara, M. E., Hogan, M. J., Le, N., Muramatsu, H., Lam, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68080-x · Cited by 17
Zhao, Y., Liu, C., Zhang, X., Gu, T., Wang, Y., Zuo, T., Liu, S., Xu, X., & Meng, H. (2026) · ACS Nano · doi:10.1021/acsnano.5c21857 · Cited by 18
Wu, S., Wu, C., Cho, H., & Chiang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169453 · Cited by 16
Greig, J. A., Chorazeczewski, J. K., Chowdhary, V., Smith, M. K., Jennis, M., Tarrant, J. C., Buza, E. L., Coughlan, K. A., Martini, P. G. V., & Wilson, J. M. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.007 · Cited by 16
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
mRNA biotherapeutics landscape for rare genetic disorders
Iyer, V. R., Praveen Reddy., P., Kaduskar, B., Moharir, S. C., & Mishra, R. K. (2024) · Journal of Biosciences · doi:10.1007/s12038-023-00415-6 · Cited by 17
Chemical Design Strategy of Ionizable Lipids for In Vivo mRNA Delivery
He, Z., Liu, Z., & Chen, Y. (2024) · ChemMedChem · doi:10.1002/cmdc.202400199 · Cited by 16
Mantri, P., Juneja, B., Henderson, S., Koufos, E., Moon, Y., Dayeh, D. M., Grandi, D. D., Fu, Y., Muthusamy, K., Ihnat, P. M., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116352 · Cited by 16
A Cell-Free Kinetic Analysis of Ionizable Lipid Hydrolysis
Couture‐Senécal, J., Natraj, J., & Khan, O. F. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c02399 · Cited by 16
Corosolic acid derivative-based lipid nanoparticles for efficient RNA delivery
Liu, Y., Zhang, R., Yang, Y., Liu, X., & Jiang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.073 · Cited by 16
Khare, S., Niharika, N., Singh, A., Hussain, I., Singh, N. B., & Singh, S. C. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-04181-3 · Cited by 16
Qin, S., Huang, H., Xiao, W., Chen, K., He, X., Tang, X., Huang, Z., Zhang, Y., Duan, X., Fan, N., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.010 · Cited by 16
Lipid nanoparticles: A delicate nucleic acid delivery system to be further explored
Ma, R., Li, Y., Su, Y., Chen, P., Xie, S., Tan, W., & Liu, X. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102586 · Cited by 15
Vu, M. N., Pilapitiya, D., Kelly, A., Koutsakos, M., Kent, S. J., Juno, J. A., Tan, H., & Wheatley, A. K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102547 · Cited by 15
Casmil, I. C., Friesen, J. J., Bathula, N. V., Strumpel, A., Ho, C.-H., Guez, I., Kong, K. Y. S., Varley, A., Miyake-Stoner, S. J., Aliahmad, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202508907 · Cited by 17
Circular RNA-based protein replacement therapy mitigates osteoarthritis in male mice
Suo, J., Li, L., Tan, W., Yin, X., Wang, J., Shao, R., Sun, S., Guo, S.-K., Feng, J., Gao, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63343-z · Cited by 15
Garcia-Dominguez, D., Henry, C., Ma, L., Jani, H., Amato, N. J., Manning, T., Freyn, A. W., Davis, H. L., Hsiao, C. J., Li, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948335 · Cited by 15
Fopase, R., Panda, C., Rajendran, A. P., Uludağ, H., & Pandey, L. M. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1112755 · Cited by 16
Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment
Wang, S., Zhu, Y., Du, S., & Zheng, Y. (2024) · Cells · doi:10.3390/cells13070568 · Cited by 16
Selvam, A. K., Wiklander, R. J., Gramignoli, R., Achour, A., Salter, H., & Björnstedt, M. (2021) · Antioxidants · doi:10.3390/antiox10071094 · Cited by 15
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
Darling, T. L., Ying, B., Whitener, B. M., VanBlargan, L. A., Bricker, T. L., Liang, C.-Y., Joshi, A., Bamunuarachchi, G., Seehra, K., Schmitz, A. J., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.009 · Cited by 15
Segalla, G. (2023) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v3i1.84 · Cited by 16
Couture‐Senécal, J., Tilstra, G., & Khan, O. F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.02.606386 · Cited by 16
ALC-0315 Lipid-Based mRNA LNP Induces Stronger Cellular Immune Responses Postvaccination
Song, Z., Jin, L., Jiao, L., Yu, R., Liu, H., Zhang, S., Hu, Y., Sun, Y., Li, E., Zhao, G., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00995 · Cited by 15
Rational Design of Unsaturated, Thioether Ionizable Lipids for Enhanced In Vivo mRNA Delivery
Samaridou, E., Simon, J., Beck‐Broichsitter, M., Davidson, G. R., & Levkin, P. A. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501037 · Cited by 17
Heiser, B. J., Lewis, M. M., Zerankeshi, M. M., Netemeyer, E. K., Hernandez, A. M., Marras, A. E., & Ghosh, D. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00061k · Cited by 15
Design of cationic ionizable lipids for the delivery of therapeutic nucleic acids
Atmuri, N. D. P., Saadati, F., Kulkarni, J. A., Witzigmann, D., Cullis, P. R., & Ciufolini, M. A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101585 · Cited by 14
Danz, H., Dauner, A. L., Sharma, S., Babiceanu, M., Clark, N., Ontiveros, R. J., Amezquita, R. A., Zhilin-Roth, A., Reyes, E., Khoo, C., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01263-1 · Cited by 15
Meerasa, S. S., Ahmad, A., Khan, A. A., Haque, S., & Saleem, I. Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126263 · Cited by 14
Saini, A., Li, S., Wang, Z., Plebanski, M., & Ju, Y. (2026) · ACS Nano · doi:10.1021/acsnano.6c00334 · Cited by 15
Translation of in vitro-transcribed RNA therapeutics
von der Haar, T., Mulroney, T. E., Hedayioglu, F. D. L., Kurusamy, S., Rust, M., Lilley, K. S., Thaventhiran, J. E. D., Willis, A. E., & Smales, C. M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1128067 · Cited by 14
Broudic, K., Laurent, S., Perkov, V., Simon, C., Garinot, M., Truchot, N., Latour, J., & Désert, P. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4548 · Cited by 15
A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques
Bian, T., Hao, M., Zhao, X., Zhao, C., Luo, G., Zhang, Z., Fu, G., Lu, Y., Chen, Y., Wang, Y., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00763-2 · Cited by 14
Shi, J., Yin, H., Sun, Q., Teng, R., Zhu, Y., & Du, J. (2024) · Chemistry of Materials · doi:10.1021/acs.chemmater.4c00219 · Cited by 14
Leveraging high-throughput screening technologies in targeted mRNA delivery
Zhang, Y., Gao, Z., Yang, X. Q., Xu, Q., & Lu, Y. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101101 · Cited by 16
Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease
Yang, T., Ge, J., Huang, L., Zhu, X., Zhang, D., Tang, S., Zhao, J., Ma, Y., Long, M., Bo, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt9694 · Cited by 14
Koyra, N., Yu, H., Drummond, C. J., Zhai, J., & Dyett, B. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2518225 · Cited by 15
Advances in Development of mRNA-Based Therapeutics
Huang, L., Zhang, L., Li, W., Li, S., Wen, J., Li, H., & Liu, Z. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_222 · Cited by 16
Vaccine Development for Coronavirus (SARS-CoV2) Disease (Covid-19); Lipid Nanoparticles
Malabadi, R. B., Kolkar, K. P., Meti, N. T., & CHALANNAVAR, R. K. (2021) · International journal of research and scientific innovation · doi:10.51244/ijrsi.2021.8312 · Cited by 14
Kim, H. J., Kim, A., & Miyata, K. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100428 · Cited by 14
Truong, L. B., Medina-Cruz, D., & Mostafavi, E. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125185 · Cited by 17
Ren, X., Su, D., Shi, D., & Xiang, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1272850 · Cited by 15
Bayat, M., Asemani, Y., & Najafi, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107679 · Cited by 15
Applying machine learning to identify ionizable lipids for nanoparticle-mediated delivery of mRNAPreprint
Lewis, M. M., Beck, T. J., & Ghosh, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.09.565872 · Cited by 14
Wang, X., Tian, Z., Wang, M., Cai, X., Yang, S., Zeng, J., Fang, Y., Bai, X., Wang, P., Sun, Y., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06924-2 · Cited by 14
Guruge, A. G., He, Y., Clulow, A. J., Pouton, C. W., & Chalmers, D. K. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101596 · Cited by 14
Takechi‐Haraya, Y. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00158 · Cited by 13
Xu, X., Cui, L., Zhang, Y., & Gu, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.023 · Cited by 13
Kordyukova, L. V., & Shanko, A. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921070026 · Cited by 13
Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Wang, S., Guo, B., Wang, H., & Yang, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105547 · Cited by 14
Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine
Finn, M. B., Penfound, T. A., Salehi, S., Ogega, C. O., Dold, C., Plante, O. J., & Dale, J. B. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126205 · Cited by 13
Marecki, E. K., Oh, K. W., Knight, P. R., & Davidson, B. A. (2024) · Biomicrofluidics · doi:10.1063/5.0201465 · Cited by 13
Chen, Y., Lombaerde, E. D., Bugler-Lamb, A. R., Zhong, Z., Schuijs, M. J., Gomez, C. M. B., Baere, J. D., Gontsarik, M., Lauwers, H., Deswarte, K., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202506954 · Cited by 13
Conte, M., Carofiglio, M., Rosso, G., & Cauda, V. (2023) · Nanomaterials · doi:10.3390/nano13152250 · Cited by 14
Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside
Kenoosh, H. A., Pallathadka, H., Hjazi, A. M., Al‐Dhalimy, A. M. B., Zearah, S. A., Ghildiyal, P., Al‐Mashhadani, Z. I., Mustafa, Y. F., Hizam, M. M., & Elawady, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3954 · Cited by 15
The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing
Hassanzadeh, P. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119289 · Cited by 13
Bispecific antibody targeting of lipid nanoparticlesPreprint
Amabile, A., Phelan, M., Yu, Z., Silva, P., Marks, A. R., Morlà‐Folch, J., Sohn, M., Mollaoglu, G., Falcomatà, C., Teunissen, A. J. P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.20.629467 · Cited by 14
Acid‐Responsive Polymer Additives Increase RNA Transfection from Lipid Nanoparticles
Cheung, T. H., Fuchs, A., & Shoichet, M. S. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202413220 · Cited by 13
Lew, B., Chhabra, S., Lewis, J. A., Wagoner, A. C., Hsu, A., Halaby, S. L., Sharma, P., Murray, J. K., Kinderman, F. S., Piedmonte, D. M., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00068 · Cited by 12
Decrypting the Immune Symphony for RNA Vaccines
Weidensee, B., & Sahu, I. (2025) · Vaccines · doi:10.3390/vaccines13080882 · Cited by 13
He, Y., Pilkington, E. H., Kang, H. J., Fong, W., Clulow, A. J., Johnston, A. P. R., & Pouton, C. W. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101578 · Cited by 12
Kim, S., Oh, T., Lee, H., & Nam, J. (2022) · Materials Chemistry Frontiers · doi:10.1039/d2qm00039c · Cited by 12
Homma, K., Miura, Y., Kobayashi, M., Chintrakulchai, W., Toyoda, M., Ogi, K., Michinishi, J., Ohtake, T., Honda, Y., Nomoto, T., et al. (2024) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2024.2338785 · Cited by 12
Reitemeier, J., Metro, J., & Bohn, P. W. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116457 · Cited by 12
Sandelius, Å., Naseer, H., Lindqvist, J., Wilson, A., & Henderson, N. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2360361 · Cited by 12
Desai, P., Karl, C. E., Ying, B., Liang, C.-Y., García‐Salum, T., Santana, A. C., ten-Caten, F., Urban, J. F., Elbashir, S. M., Edwards, D. K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado1941 · Cited by 13
Jeon, J. H., Zhu, H., Qin, J., Wang, L., Mou, S., Langston, L. K., Marasini, R., Chen, J., Xu, R., Li, S., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s527822 · Cited by 12
Clinical Development of mRNA Vaccines: Challenges and Opportunities
August, A., Brito, L., Paris, R., & Zaks, T. Z. (2022) · Current topics in microbiology and immunology · doi:10.1007/82_2022_259 · Cited by 12
Self-citationErmilova, I., & Swenson, J. (2023) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2023.105294 · Cited by 12
Messenger RNA Therapy for Female Reproductive Health
VanKeulen‐Miller, R., & Fenton, O. S. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00803 · Cited by 13
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Sa-nguanmoo, N., Namdee, K., Khongkow, M., Ruktanonchai, U., Zhao, Y., & Liang, X. (2021) · Nano Research · doi:10.1007/s12274-021-3832-y · Cited by 12
Lipid Nanoparticle-based mRNA Therapeutics for Infectious Diseases
Kumar, R., Kommineni, N., Aadil, K. R., Desai, N., Bunekar, N., Salave, S., Bulusu, R., Kumar, D., & Vora, L. K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126420 · Cited by 12
Novel Lipid Nanoparticle (LNP) Delivery Systems Enabling the Advancement of RNA Therapeutics
Zhang, H., Han, S., Zhang, X., Ma, J., Jin, L., Wang, Y., Ma, Y., Ma, T., Yu, F., & Song, G. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505340 · Cited by 15
Katopodi, T., Petanidis, S., Grigoriadou, E., Anestakis, D., Charalampidis, C., Chatziprodromidou, I. P., Floros, G., Eskitzis, P., Zarogoulidis, P., Koulouris, C., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040455 · Cited by 11
Metadata
- Authors
- Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M. J., Senn, J. J., Stanton, M. G., Almarsson, Ö., Ciaramella, G., & Brito, L. A.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Brito, Luis A.
- ORCID
- Venue
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 15
- Pages
- 1-11
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC6383180
- OpenAlex
- W2914060533
- Cited by
- 927
- References
- 35
- Citations by year
- 2026: 141 · 2025: 202 · 2024: 162 · 2023: 140 · 2022: 128 · 2021: 114 · 2020: 35 · 2019: 5
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moderna Therapeutics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, intramuscular administration, ionizable lipids, biodegradable lipids, immunogenicity, tolerability, innate immune activation, non-human primates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
